Takeda shutting US vaccine R&D sites in global restructure

By Dan Stanton

- Last updated on GMT

Dengue fever is one of the vaccines in Takeda's pipeline
Dengue fever is one of the vaccines in Takeda's pipeline

Related tags Influenza Clinical trial

Takeda is closing three US R&D facilities and relocating its global HQ to a site in Massachusetts as part of plans to consolidate its vaccine business.

This week Takeda has announced it is reshaping its Vaccine Business Unit (VBU) operations, establishing both global and regional hubs in order to support its norovirus, dengue and seasonal influenza pipeline.

The Japan-headquartered biopharma firm initiated steps to consolidate its global R&D and manufacturing  networks back in 2013​, in order to increase efficiency and save ¥120bn ($1bn) in operational costs by 2017, and as part of this latest shake-up it is shuttering several US vaccine sites.

Over the next two years, a site in Bozeman, Montana - acquired when Takeda bought LigoCyte Pharmaceuticals in 2012​ - will close, along with the former- Inviragen​ sites in Madison, Wisconsin and Fort Collins, Colorado, while the current VBU headquarters in Deerfield, Illinois, will be relocated to a new hub in the Boston/Cambridge, Massachusetts area.

“Our sites in Bozeman, Fort Collins, Madison and Deerfield have been instrumental in bringing our dengue and norovirus programs to late stages of clinical development,” said President of Takeda’s VBU Rajeev Venkayya.

“This consolidation will help us to achieve the efficiency and operational excellence needed to execute the Phase 3 clinical programs and set the stage for global commercialization of these vaccines.”

Zurich, Switzerland will serve as a second global hub for the vaccine unit, with regional sites in Singapore and Brazil. Takeda’s vaccine manufacturing - which takes place at facilities in Hikari, Japan; Durham, North Carolina and Singen, Germany – will not be affected by the realignment.

Related topics Bio Developments Pipelines Facilities

Related news

Show more

Related product

Process optimization for mAb commercial manufacturing

Process optimization for mAb commercial manufacturing

Content provided by Catalent | 01-Jun-2023 | Product Presentation

Process characterization and validation is an important step in the product development journey and late-phase development, and it is required before transferring...

Related suppliers